PHILADELPHIA, July 07, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) on behalf of purchasers of Compass securities between May 1, 2024 through May 7, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Compass securities during the Class Period may, no later than JULY 8, 2025, seek to be appointed as a lead plaintiff rep ...

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns related to its products [1][2]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process for Investors - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified class period of the upcoming lead plaintiff deadline on July 8, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Digimarc Corporation, and investors who wish to serve as lead plaintiff must act by July 8, 2025 [2]. - The lawsuit alleges that Digimarc made false and misleading statements regarding its business operations, specifically about a large commercial partner not renewing a significant contract, which adversely affected subscription and annual recurring revenue [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking in the top four for settlements since 2013 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and securing over $438 million for investors in 2019 alone [4]. Group 3: Allegations Against DoubleVerify - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customer ad spending to closed platforms where its capabilities were limited [5]. - It is claimed that DoubleVerify's high-margin advertising optimization services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5]. - The lawsuit also points out that DoubleVerify overbilled customers for ad impressions served to bots and that its risk disclosures were misleading, leading to investor damages when the true situation was revealed [5].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false and misleading statements about ELEVIDYS, which is intended for patients with Duchenne muscular dystrophy, including significant safety risks and failure to detect severe side effects [5]. - It is alleged that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, regulatory scrutiny, and increased risk regarding the therapy's approvals [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record, including recovering hundreds of millions for investors [4]. - Investors are advised to select qualified legal counsel with a proven history in similar cases, as not all firms have comparable experience or resources [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

Here’s How Sean ‘Diddy’ Combs’ Criminal Conviction Could Help Plaintiffs In His Dozens Of Civil Lawsuits https://t.co/Zfdp2vVs1p https://t.co/Zfdp2vVs1p ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that due to these misrepresentations, PepGen was likely to halt the CONNECT2 study, leading to overstated clinical, regulatory, and commercial prospects for PGN-ED051 [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result of the misleading statements [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong reputation in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial guidance and cost trends related to Medicaid redetermination processes during the specified Class Period [1][4][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, Indiana, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Lawsuit Details - The lawsuit claims that Elevance misled investors by stating they were effectively monitoring cost trends and that premium rates negotiated with states were sufficient to cover rising Medicaid expenses [4]. - It is alleged that the company did not adequately reflect the impact of Medicaid redeterminations, which resulted in a higher utilization of Medicaid members who remained eligible, as those removed were generally healthier [5]. Investor Information - Investors who purchased Elevance securities during the Class Period have until July 11, 2025, to seek appointment as lead plaintiff representatives [2].

Here’s How Sean ‘Diddy’ Combs’ Criminal Conviction Could Help Plaintiffs In His Dozens Of Civil Lawsuits https://t.co/7ypJIGVLdq https://t.co/7ypJIGVLdq ...

The victory you got for Jay-Z seemed like classic you. You got the case dismissed. You're coming back with a defamation suit.You called the accuser's lawyer a 1800 lawyer. Why were you so aggressive in defending him. Cuz he was completely innocent and because I felt that the system was being weaponized in an improper way.And what does that tell you about the system. The system is very broken. It's probably, you know, we spend so much time talking about other things, but it is one of the original problems in ...